{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:13:36Z","timestamp":1760908416902,"version":"3.44.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.jns.2007.05.023","type":"journal-article","created":{"date-parts":[[2007,7,6]],"date-time":"2007-07-06T07:20:34Z","timestamp":1183706434000},"page":"40-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement"],"prefix":"10.1016","volume":"263","author":[{"given":"Massimiliano","family":"Filosto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Pelizzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Buzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Tentorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Broglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelangelo","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Scarpelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2007.05.023_bib1","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase II study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2007.05.023_bib2","first-page":"64a","article-title":"VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma","volume":"104","author":"Alexanian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jns.2007.05.023_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase II study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jns.2007.05.023_bib4","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1002\/cncr.21427","article-title":"Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma","volume":"104","author":"Berenson","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.jns.2007.05.023_bib5","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","article-title":"Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14\u00a0day cycle","volume":"23","author":"Hamilton","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jns.2007.05.023_bib6","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jns.2007.05.023_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jns.2007.05.023_bib8","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jns.2007.05.023_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.clon.2005.12.008","article-title":"An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib","volume":"18","author":"Stubblefield","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jns.2007.05.023_bib10","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11910-006-0009-8","article-title":"Neurologic toxicities of cancer therapies","volume":"6","author":"Cavaliere","year":"2006","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.jns.2007.05.023_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2007.05.023_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1126\/science.7624798","article-title":"Role of the ubiquitin\u2013proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27","volume":"269","author":"Pagano","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.jns.2007.05.023_bib13","first-page":"2649","article-title":"In vivo ubiquitination and proteasome-mediated degradation of p53(1)","volume":"56","author":"Maki","year":"1996","journal-title":"Cancer Res"},{"year":"2004","series-title":"Velcade\u2122 (bortezomib) for injection. Prescribing information","author":"Millennium Pharmaceuticals, Inc","key":"10.1016\/j.jns.2007.05.023_bib14"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07003826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X07003826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:39:44Z","timestamp":1758382784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X07003826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":14,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0022510X07003826"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2007.05.023","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2007.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}